Diabetes Res Clin Pract 170:108532
Semaglutide offers stronger long-term evidence, with sustained weight loss in trials lasting 68 weeks or longer, making it better suited for chronic weight management
Sources: 1 Bloomberg Intelligence, BI Disease Overview: Obesity
According to UAB clinicians, patients are presenting with dangerously low blood sugar, severe nausea, and pancreatitisoften the result of unsupervised use or improper titration
Do not warm it beyond room temperature
Several retrospective studies associated the drug class with lower glaucoma risk and reduced ocular hypertension incidence, while preclinical work demonstrated reduced retinal ganglion cell loss and optic nerve damage in experimental models. The experimental literature also points to inflammatory modulation, oxidative stress reduction and retinal ganglion cell survival pathways as possible mechanisms. Smaller studies evaluating IIH and DED reported reductions in intracranial pressure and improved ocular surface parameters, respectively, among treated patients. READ MORE: Blinding Disease-Weight Loss Drug Link: EMA Announces Start of Semaglutide Investigation The evidence base still has limits The review flagged recurring methodological constraints across the literature: reliance on retrospective EHR analyses and ICD-based coding, heterogeneous ocular endpoints, inconsistent imaging and limited longitudinal follow-up
